The Mechanism of Low Dose Immunotherapy (LDI)
July 7, 2024

Today, I want to dive into the proposed mechanism of action behind Low Dose Immunotherapy (LDI) and its predecessors like EPD and LDA. Understanding how these therapies work can shed light on their effectiveness in treating various immune-mediated conditions.

Origins and Conceptual Framework

The original discovery by Dr. Leonard McEwen’s involved beta glucuronidase, an enzyme found in gut bacteria and believed to signal immune tolerance when introduced in small doses alongside diluted antigen mixtures. This discovery formed the basis of EPD, where the term “Enzyme Potentiated Desensitization” hinted at the therapy’s mechanism—promoting immune tolerance rather than mere desensitization.

Evolution to LDI

As the concept evolved into LDA (Low Dose Allergy Therapy) and eventually LDI, the focus remained on using highly diluted antigen mixtures, sometimes up to a trillion-to-one dilution. This approach challenges conventional immunotherapy norms by aiming to trigger a regulatory response from immune cells, particularly regulatory T lymphocytes, which play a pivotal role in immune tolerance.

Rethinking the Role of Enzymes

Initially, it was thought that beta glucuronidase was crucial for initiating immune tolerance responses. However, my clinical observations and experiments have led me to reconsider this hypothesis. Variations in antigen dosages have shown that the effectiveness of LDI primarily hinges on the antigen dose rather than the presence of the enzyme. In fact, trials omitting the enzyme yielded similar outcomes, suggesting its role may not be as pivotal as once believed.

Energetic Interactions

Beyond molecular interactions, I propose that LDI’s initial impact on the immune system operates at an energetic or vibrational level. This hypothesis is supported by treatments requiring extreme dilutions, such as 20C (10 to the 40th dilution), where conventional molecular interactions seem implausible. This energetic interaction sets the stage for subsequent measurable effects on immune responses, including reductions in antibodies, cell-mediated responses, and inflammatory markers.

Undeniable Efficacy

While the precise mechanisms underlying LDI continue to elude us, the therapy’s clinical efficacy remains undeniable for many patients with immune-mediated conditions. Our focus remains on delivering tangible improvements in health outcomes through personalized treatment strategies.

In essence, Low Dose Immunotherapy represents a paradigm shift in immunological treatments, offering a nuanced approach to managing immune disorders.